Compare DexCom, Inc. (DXCM) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Trade Desk Inc — how do they compare? DexCom, Inc. trades at $77.81 (market cap $28.06B), while Trade Desk Inc trades at $19.18 (market cap $9.11B). The key difference: DexCom, Inc. is far larger — about 3.1× Trade Desk Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | TTD | |
|---|---|---|
Market Cap | $28.06B | $9.11B |
Sector | Health | Technology |
52-Week High | $89.53 | $89.76 |
52-Week Low | $54.84 | $17.33 |
Enterprise Value | $27.03B | $8.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
TTD trades at $18.94, down 4.3% on the day, reflecting recent bearish momentum amid slowing revenue growth concerns. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company maintains strong profitability with a 77.83% gross margin and 14.57% net income margin, though Q1 2026 earnings missed expectations. Recent news highlights executive appointments and expansion in Japan's advertising market, while analyst sentiment remains divided with a $25.23 consensus price target.
The outlook for TTD balances strong cash flow generation and market position against growth deceleration and competitive pressures. Investment opportunity lies in potential valuation recovery if CTV advertising momentum accelerates, but risks include market share loss to larger rivals and execution challenges in maintaining double-digit expansion. The stock's current discount to analyst targets suggests upside if operational trends stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
